Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEDM+CEDBT for Predicting pCR After Neoadjuvant Chemotherapy in Breast Cancer
NCT06220214Phase 1Recruiting
- Sponsor
- Alison Stopeck
- Start
- Mar 2024
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Alison Stopeck. Primary endpoint: Accuracy of (CEDM+CEDBT) to predict Neoadjuvant Chemotherapy treatment effects at 24 weeks. Started Mar 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06220214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06220214.